Type D, or distressed personality and CHD. A new risk factor?

Slides:



Advertisements
Similar presentations
Rahe, Mahan and Arthur
Advertisements

Depression, Vital Exhaustion and recurrent heart disease.
Lecture 9 Type A behaviour, hostility and CHD. Lecture 8 Reading There is material on Type A and hostility in the standard texts and general papers. See.
How would you explain the smoking paradox. Smokers fair better after an infarction in hospital than non-smokers. This apparently disagrees with the view.
Chapter 9: The relationship between physical activity and anxiety and depression Can physical activity beat the blues and help with your nerves?
Lecture 6. Stress and CV disease. Evidence from animal models.
Depression, Vital Exhaustion and recurrent heart disease.
Deriving Biological Inferences From Epidemiologic Studies.
Valsartan Antihypertensive Long-Term Use Evaluation Results
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
Johan Denollet, PhD the heart failure patient ? Why is a dedicated cardiologist not sufficient for The Netherlands.
Heart and Mind Connections: Integrated Strategies for Greater Health Presentation to Senior Leadership.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July-August 2007.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
1 Comorbidity of Alcohol and Psychiatric Problems NIAAA Social Work Education Module 10E (revised 3/04)
The Early Childhood Roots of Adult Health: Closing the Gap Between What We Know and What We Do JACK P. SHONKOFF, M.D. JULIUS B. RICHMOND FAMRI PROFESSOR.
Managing depression in people with long term conditions Chris Dickens Professor of Psychological Medicine Peninsula College of Medicine and Dentistry.
Rivka Herman 1 *,RN. M.Sc Michal Libergal 1 *, PhD; David Rott 2, MD Michal Libergal 1 *, PhD; David Rott 2, MD 1 Henrietta Szold Hadassah-Hebrew University.
Spring 2015 ETM 568 Callier, Demers, Drabek, & Hutchison Carter, E. J., Pouch, S. M., & Larson, E. L. (2014). The relationship between emergency department.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Management of Stable Angina SIGN 96
Citation Zajac, I. T., Duncan, A., Flight, I., Wilson, C., Wittert, G., & Turnbull, D (2015). The Relationship of Self-Rated Health and Health Priorities.
Web of Causation; Exposure and Disease Outcomes Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
Benjamin B. Lahey, University of Chicago Student Leadership Presentation by Travis J. Pashak.
Stress and heart disease: a few basics a model and evidence on triggering heart attacks.
ASSOCIATION OF HIGH-DENSITY LIPOPROTEIN CHOLESTEROL WITH INCIDENT CARDIOVASCULAR EVENTS IN WOMEN, BY LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN.
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Omega-3 Polyunsaturated Fatty Acids and Cardiovascular.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: AACVPR/ACC/AHA 2007 Performance Measures on Cardiac.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.
CoRPS Center of Research on Psychology in Somatic diseases Inflammation, Mediation and Type D personality Multiple inflammatory biomarkers as mediators.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Percutaneous Coronary Intervention Complications.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Figure 1 A flow chart describing the systematic process followed for article selection.  From: A systematic review of cost-effectiveness of percutaneous.
Copyright © 2013 American Medical Association. All rights reserved.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Chapter 7 The Hierarchy of Evidence
Catheter-Based Treatment of Coronary Artery Disease
RAAS Blockade: Focus on ACEI
Diabetes mellitus in patients undergoing percutaneous drug-eluting stent implantation: short and long-term results Claudio Moretti, M.D. Division of Cardiology,
Although adverse childhood events may account for only a small proportion of the current obesity epidemic in the U.S. (Alvarez et al., 2007), risk of obesity.
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Figure 1 Milestones in coronary angioplasty
Significance of Periprocedural Myocardial Infarctions in Percutaneous Coronary Interventions A New Look at an Old Topic Abhiram Prasad, MD, FRCP, FESC,
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.
Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Rona Moss-Morris Professor of Psychology as Applied to Medicine
Glenn N. Levine et al. JACC 2011;58:e44-e122
Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.
Davide Capodanno et al. JCIN 2009;2:
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
The Clinical Significance and Management Implications of Chronic Total Occlusion Associated With Surgical Coronary Artery Revascularization  Lorenzo Azzalini,
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Type D, or distressed personality and CHD. A new risk factor?

Reading Type D is fairly new concept and may not figure in standard texts. Pedersen SS & Denollet (2003) Type D personality, cardiac events and impaired quality of life : A review. European Journal of Cardiology, Prevention and Rehabilitation. 10, Available free Important reading on this topic. Pedersen, S.S., & Denollet, J. (2006). Is Type D personality here to stay? Emerging evidence across cardiovascular disease patient groups. Current Cardiology Reviews, 6(2), Ask me about this paper Suls J & Bunde J (2005) Anger, anxiety, and depression as risk factors for Cardiovascular disease: the problems and implications of overlapping affective dispositions. Psychological Bulletin, 131, Complex paper which helpfully summarises evidence for these negative emotions as risk factors (useful for other parts of the course) and argues that there may be considerable overlap between them and the link is the tendency to experience strong negative emotions. Not specifically on Type D, but relates to it as well as the other psychological risk factors. Valuable current paper but not essential reading.

Measuring Type D. DS14 (Denollet, (2005) Psychosomatic Medicine, 67, ) Assesses Negative affectivity (NA): tendency to feel dysphoria, anxiety and irritability” “I often feel unhappy”, I am often down in the dumps” “ I am often in a bad mood” Social Inhibition (SI): discomfort in social situations, lack of social poise, avoid confrontation in social interaction. “I find it hard to start a conversation”, “I would rather keep people at a distance” “I often feel inhibited in social interactions” Factor analysis of 3678 people (CHD & Healthy). Two clear factors. Cut off of 10 on both scales advocated.

Appears to relate to CHD & hypertension (a CHD risk factor)

If Type D is a personality measure it should be stable over time, unlike mood & health. Consider effects of rehabilitation

The early studies CHD patients recruited at cardiac rehabilitation. Does this show that both NA & SI have to be high to predict cardiac events?

303 CHD patients recruited at cardiac rehabilitation. Type D personality Odd Ratio 4.1 ( ) when allowing for factors related to severity of MI. Figure suggests NA x SI interaction.

Not Just MI, or even CHD

Type D and prognosis after medical interventions for CHD 875 patients received drug-eluting stents Percutaneous coronary intervention (PCI) (next slide) Type D measured 6 months later (SI from DS14, NA from HADS and DS14, why extra measures of NA?) Outcome: Major Adverse Cardiac Events (MACE: MI, CABG or PCI) 9 months after Type D assessed Type D the main predictor of MACE. HR (Hazard Ratio) Only other significant predictor, previous coronary bypass (CABG) DenolletJ et al, (2006). European Heart Journal, 27,

Mechanism? Few studies. (HPA Hypothalamic- pituitary-adrenal axis)

When is a risk factor casual Apply to Type D TemporalityStrength of relationship ConsistencyBiological gradient Biological PlausibilityCoherence Outcome SpecificityIntervention evidence

Causality (cont) Temporality: are there prospective studies demonstrating that x precedes development of disease? Strength of relationship: How much of the variance in disease incidence explained by x? Consistency: Are studies consistent in their findings? Biological gradient: is severity and/or frequency of x associated with increasing risk of disease? Biological plausibility: what pathogenic mechanisms link x to disease?

Causality 3 Coherence: Does evidence for the relation between x and disease come from different samples (population, patient, animal models)? Outcome specificity: Is the risk associated with x exclusive to one disease? Intervention Effects: Is the disease prevented if x is treated early enough?